Related Experiment Video
Updated: Jun 8, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Intronic polymorphisms of cytochromes P450
Magnus Ingelman-Sundberg1, Sarah C Sim
1Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE-17177 Stockholm, Sweden. magnus.ingelman-sundberg@ki.se
Human Genomics
|September 18, 2010
Summary
Cytochrome P450 (CYP) enzymes, crucial for drug metabolism, exhibit significant genetic variations. Identifying these polymorphisms, like CYP2D6 and CYP3A5 variants, is key to understanding drug response differences.
Area of Science:
- Pharmacogenomics
- Molecular Biology
- Drug Metabolism
Background:
- Cytochrome P450 (CYP) enzymes are highly polymorphic, significantly impacting drug metabolism.
- The cytochrome P450 family 2 (CYP2) gene family contains the majority of described allelic variants, with 252 identified alleles.
- Intronic polymorphisms, while less common, include critical variants like CYP2D6*4, CYP2D6*41, CYP3A5*3, and CYP3A5*5, affecting enzyme activity.
Purpose of the Study:
- To highlight the significance of genetic polymorphisms in cytochrome P450 enzymes for drug metabolism.
- To discuss the challenges in identifying and characterizing these variant alleles.
- To emphasize the potential of next-generation sequencing in uncovering new intronic mutations affecting CYP-mediated metabolism.
Main Methods:
- Analysis of existing literature on cytochrome P450 gene polymorphisms.
- Review of identified allelic variants, focusing on those with significant impact on enzyme activity (e.g., CYP2D6, CYP3A5).
- Consideration of phenotypic data and historical challenges in variant discovery.
Main Results:
- Key intronic polymorphisms (CYP2D6*4, CYP2D6*41, CYP3A5*3, CYP3A5*5) significantly alter CYP2D6 and CYP3A5 activity.
- Discovery of functionally important variants has historically been challenging and time-consuming.
- Next-generation sequencing is expected to identify further intronic mutations responsible for inter-individual metabolic differences.
Conclusions:
- Genetic variations in cytochrome P450 enzymes are critical determinants of inter-individual differences in drug and steroid metabolism.
- Continued research, aided by advanced sequencing technologies, is essential for a comprehensive understanding of pharmacogenomic variability.
- Identifying novel polymorphisms will improve predictions of drug efficacy and toxicity.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...